Tata 1mg narrows healthcare loss as FY26 turnover rises 21%

Tata 1mg Healthcare reported FY26 turnover of ₹2,439.8 crore, while its net loss narrowed to ₹310 crore. The Tata Digital-owned platform is expanding diagnostics, non-metro access and rapid medicine delivery, alongside plans to raise $300 million externally.

— Source publishedMon, 27 Jul, 2026, 21:48 IST·First seen Mon, 27 Jul, 2026, 21:50 IST·Source Mint

What happened

Tata 1mg’s healthcare turnover rose 21% to ₹2,439.8 crore in FY26 as its loss narrowed to ₹310 crore. The e-pharmacy is expanding diagnostics and non-metro

Key facts

  • Tata 1mg Healthcare FY26 turnover: ₹2,439.8 crore, up 21% from ₹2,016.5 crore
  • Tata 1mg Healthcare FY26 net loss: ₹310 crore versus ₹341.8 crore
  • Tata 1mg Technologies FY26 turnover: ₹496.1 crore, up 32% from ₹375.5 crore
  • Tata 1mg Technologies FY26 PAT: ₹17.5 crore versus ₹65.4 crore
  • Tata Sons investment in Tata 1mg Technologies: ₹1,335 crore
  • Planned external capital raise: $300 million
  • Tata Digital FY26 GMV: ₹46,515 crore
  • Tata Digital FY26 revenue: ₹35,990 crore versus ₹32,188 crore
  • Tata Digital FY26 net loss: ₹4,974 crore versus ₹4,610 crore

Why this matters

Tata 1mg’s expansion in diagnostics and last-mile medicine delivery makes it a more consequential healthcare-platform partner or competitor, with fresh external capital likely to accelerate capability-building and market consolidation.

What to watch

  • Terms, timing and investor mix of the planned $300 million raise.
  • FY27 loss trajectory relative to revenue growth and evidence of improved contribution margins.
  • Expansion pace and service-level claims for rapid medicine delivery.
  • Diagnostics revenue mix, test volumes and utilization of collection-center capacity.
  • Repeat-order rates in chronic medicines and subscription/refill adoption.
  • Competitive pricing and delivery moves by PharmEasy, Netmeds, Apollo 24|7 and quick-commerce platforms.
  • Whether Tata Digital increases, reduces or restructures financial support for the business.
  • Prioritize external fundraising to finance expansion without increasing Tata Digital's funding burden.
  • Expand rapid medicine delivery selectively in dense urban clusters where basket density can support unit economics.
  • Use diagnostics, subscriptions and chronic-care refill programs to increase repeat purchases and customer lifetime value.
  • Build non-metro access through partner pharmacies, collection centers and regional logistics rather than fully owned infrastructure.
  • Tighten contribution-margin tracking by city, delivery speed and customer cohort as growth investment increases.

Also reported by